Alaunos Therapeutics Overview
Valuation check: TCRT's ROE is -615.03%, below the Healthcare sector average of 21.18%.
Get informed when a big investor buys or sells
+ Follow-615.03%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Alaunos Therapeutics (TCRT) currently reports a ROE of -615.03%. That is below the Healthcare sector average of 21.18%. Use the charts on this page to explore Alaunos Therapeutics's ROE history and peer comparisons.
Alaunos Therapeutics's ROE of -615.03% is lower than the Healthcare sector average of 21.18%. That is roughly 3003.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Alaunos Therapeutics's current -615.03% should be judged against Healthcare norms (sector average: 21.18%) and against TCRT's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -615.03%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.18%. From there, open related valuation or income-statement pages for Alaunos Therapeutics, and consider following TCRT for alerts when major investors trade the stock.
Alaunos Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -615.03% versus a sector average near 21.18%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TCRT with unrelated industries.
